Click here to view the Premera Blue Cross Medical Policy Updates » December 2024 Medical…
BCBS Federal Employee Program (FEP) Medical Policy Updates – April 2021
April 2021 BCBS Federal Employee Program (FEP) Medical Policy Updates:
- 5HT3 Antagonists
- Abilify Mycite aripiprazole with sensor
- Abstral fentanyl sublingual
- Actemra tocilizumab 1
- Acthar gel corticotropin
- Actimmune interferon gamma1B
- Actiq transmucosal fentanyl
- Adakveo crizanlizumabtmca
- Adcetris brentuximab vedotin
- Adcirca Alyq tadalafil
- Adempas riociguat
- AdiposeDerived Stem Cells in Autologous Fat Grafting
- Aemcolo rifamycin
- Afinitor everolimus
- Afrezza insulin human
- Aldara imiquimod
- Aldurazyme laronidase
- Alecensa alectinib
- Alferon N interferon alfaN3
- Aliqopa copanlisib
- Alpha1 Proteinase Inhibitors
- Alprostadil prostaglandin E1
- Alunbrig brigatinib
- Amantadine ER
- Amerge naratriptan
- Aminolevulinic Acid
- Amitiza lubiprostone
- Amphetamines
- Ampyra dalfampridine
- Anabolic Steroids
- Analysis of Human DNA in Stool Samples as a Technique for CRC
- Anesthetic Powders
- Anjeso meloxicam injection
- Anthelmintic Drugs
- Antifungal and Antibiotic Powders
- Anti-inflammatory Pain Powders
- Aranesp darbopoetin alfa
- Arcalyst rilonacept
- Arikayce amikacin liposome inhalation suspension
- ART Drugs
- Arzerra ofatumumab
- Asparlas calaspargase
- Assays of Genetic Expression in Tumor Tissue as a Technique to
- Atgam lymphocyte immune globulin
- Aubagio teriflunomide
- Austedo deutetrabenazine
- Axert almotriptan
- Ayvakit avapritinib
- Azedra iobenguane I 131
- Baclofen powder
- Balversa erdafitinib
- Baraclude entecavir tablets
- Bavencio avelumab
- Baxdela delafloxacin
- Beleodaq belinostat
- Benlysta belimumab
- Berinert C1 esterase inhibitor
- Besponsa inotuzumab ozogamicin
- Bevacizumab
- Bioengineered Skin and Soft Tissue Substitutes
- Biomarker Testing in Breast Cancer final
- Blenrep belantamab mafodotinblmf 1
- Blincyto blinatumomab
- Bone Mineral Density Studies
- Bosulif bosutinib
- Botox onabotulinum toxin A
- Braftovi encorafenib
- Brineura cerliponase alfa
- Brukinsa zanubrutinib
- Buphenyl sodium phenylbutyrate
- Butalbital Analgesics
- Butrans buprenorphine patch
- Bynfezia octreotide acetate
- Cablivi caplacizumabyhdp
- Cabometyx cabozantinib
- Calquence acalabrutinib
- Cannabinoids
- Caprelsa vandetanib
- Carbaglu carglumic acid
- Cardiovascular Risk Panels
- Cardioverter Defibrillators
- Celebrex celecoxib
- Ceprotin protein C
- Cerdelga eliglustat
- Cerezyme imiglucerase
- CGM Supplies
- Chemical Peels
- Cholbam cholic acid
- Cholestyramine powder
- Cialis tadalafil
- Cimzia certolizumab pegol
- Cinqair reslizumab
- Cinryze C1 esterase inhibitor human
- Circulating Tumor DNA Management of
- Cometriq cabozantinib
- Compound High Dollar Limit
- Continuous Glucose Monitors
- Copiktra duvelisib
- Corlanor ivabradine
- Corticosteroid Powders
- Cosentyx secukinumab
- Cotellic cobimetinib
- Cresemba isavuconazonium
- Crysvita burosumabtwza
- Cyclobenzaprine powder
- Cyclosporine Ophthalmics
- Cyramza ramucirumab
- Danyelza naxitamabgqgk
- Daraprim pyrimethamine
- Darzalex daratumumab
- Darzalex Faspro daratumumab and hyaluronidasefihj
- Daurismo glasdegib
- Demser metyrosine
- Diacomit stiripentol
- Dojolvi triheptanoin
- Dopamine Transporter SinglePhoton Emission Computed Tomography
- Doptelet avatrombopag
- Doxepin cream 5
- Doxylamine Pyridoxine
- Drug Testing in Pain Management and Substance Use Disorder Treatment
- Dsuvia sufentanil
- Dupixent dupilumab
- Duragesic patch fentanyl
- Durlaza aspirin
- Dysport abobotulinum toxin A
- Ecoza econazole
- Egrifta SV tesamorelin
- Elaprase idursulfase
- Elelyso taliglucerase alfa
- Elyxyb celecoxib
- Elzonris tagraxofusperzs
- Emflaza deflazacort
- Empliciti elotuzumab
- Enbrel etanercept
- Endari Lglutamine
- Enhertu famtrastuzumab deruxtecannxki
- Enspryng satralizumabmwge
- Entresto sacubitril valsartan
- Entyvio IV vedolizumab
- Epidiolex cannabidiol
- Epoetin alfa agents
- Erbitux cetuximab
- Erivedge vismodegib
- Erleada apalutamide
- Ertaczo sertaconazole
- Erwinaze asparaginase
- Esbriet pirfenidone
- Eucrisa crisaborole
- Evenity romosozumabaqqg
- Evomela melphalan
- Evrysdi risdiplam
- Evzio naloxone injection
- Exelderm sulconazole nitrate
- Exjade Jadenu deferasirox
- Exondys 51 eteplirsen
- Extended Release Opioid Drugs
- Eysuvis loteprednol etabonate
- Fabrazyme agalsidase beta
- Facet Joint Denervation
- Farydak panobinostat
- Faslodex fulvestrant
- Fecal Calprotectin Testing
- Fentanyl Powder
- Fentora fentanyl buccal
- Ferriprox deferiprone
- Fintepla fenfluramine
- Firazyr icatibant
- Firdapse Ruzurgi amifampridine
- Flolan Veletri epoprostenol
- Frova frovatriptan
- Gavreto pralsetinib
- Gazyva obinutuzumab
- Gene Expression Profiling and Protein Biomarkers for Prostate Cancer Management
- Genetic and Protein Biomarkers for the Diagnosis and
- Genetic Testing for Alpha1 Antitrypsin Deficiency
- Genetic Testing for Cardiac Ion Channelopathies
- Genetic Testing for Fanconi Anemia
- Genetic Testing for FLT3 NPM1 and CEBPA Variants
- Genetic Testing for FMR1 Variants Including Fragile X Syndrome
- Genetic Testing for Neurofibromatosis
- Genetic Testing for StatinInduced Myopathy
- Genetic Testing for the Diagnosis of Inherited Peripheral Neuropathies
- GnRH GD
- Growth Hormone Adult
- Growth Hormones Pediatric
- Haegarda C1 esterase inhibitor human
- Hetlioz tasimelteon
- Humira adalimumab
- Hyaluronate Powder
- Hyaluronic Acid Derivatives
- Hydrogel Spacer use During Radiotherapy for Prostate Cancer
- Iclusig ponatinib
- Ilumya tildrakizumabasmn
- Imcivree setmelanotide
- Immune Cell Function Assay
- Infliximab
- IR Opioid Combo Drugs
- Kalbitor ecallantide
- Kalydeco ivacaftor
- Kineret anakinra
- Klisyri tirbanibulin
- Leukine sargramostim
- Leuprolide Acetate
- Magnetic Esophageal Sphincter Augmentation to Treat GERD
- Margenza margetuximabcmkb
- Measurement of Serum Antibodies to Selected Biologic Agents
- Methadone
- Methotrexate Injections
- Methylphenidates
- Molecular Analysis for Targeted Therapy or Immunotherapy of NSCLC
- Multimarker Serum Testing Related to Ovarian Cancer
- Multitarget Polymerase Chain Reaction Testing for
- Neulasta Fulphila Nyvepria Udenyca Ziextenzo
- Neupogen Granix Nivestym Zarxio
- NextGeneration Sequencing for the Assessment of MRD
- Nilandron nilutamide
- Nplate romiplostim
- Nubeqa darolutamide
- NutrientNutritional Panel Testing
- Opdivo nivolumab
- Opioid Injectables
- Opioid IR Drug Class
- Opioid Powders
- Orexin Antagonists
- Orgovyx relugolix
- Orladeyo berotralstat
- Orthopedic Applications of Stem Cell Therapy
- Otezla apremilast
- Oxlumo lumasiran
- Parathyroid Hormone Analogs
- Pharmacogenetic Testing for Pain Management
- Plugs for Anal Fistula Repair
- Proteomic Testing for Targeted Therapy in NonSmallCell Lung Cancer
- Proton Pump Inhibitors
- Provigil Nuvigil
- Pulmozyme dornase alfa
- Rituxan Hycela rituximab and hyaluronidase
- Rituximab (1)
- Rozerem ramelteon
- Ruconest C1 esterase inhibitor recombinant
- Sedative Hypnotics
- Serostim somatropin
- SGLT2 Inhibitors
- Siliq brodalumab
- Simponi golimumab 2
- Skyrizi risankizumabrzaa
- Solaraze diclofenac sodium
- Stelara ustekinumab
- Stem Cell Therapy for Peripheral Arterial Disease
- Suboxone Drug Class
- Subsys fentanyl sublingual spray
- Sumatriptan Injection
- Sunosi solriamfetol
- Symdeko tezacaftor ivacaftor
- Tagrisso osimertinib
- Takhzyro lanadelumabflyo
- Taltz ixekizumab
- Tazarotene
- Tecfidera Bafiertam Vumerity
- Topical Antifungals and Antibiotics
- Topical Corticosteroids
- Topical Products with Quantity Limits
- Topical Rosacea Agents
- Transanal Endoscopic Microsurgery
- Tremfya guselkumab
- Tretinoin
- Trijardy XR empagliflozin linagliptin metformin
- Trikafta elexacaftor tezacaftor ivacaftor
- Unituxin dinutuximab
- Upneeq oxymetazoline
- Velcade bortezomib
- Wakix pitolisant
- Winlevi clascoterone
- Wireless Capsule Endoscopy
- Xalkori crizotinib
- Xeljanz tofacitinib
- Xenazine tetrabenazine
- Xeomin incobotulinumtoxin A
- Xhance fluticasone
- Xiidra lifitegrast
- Xofluza baloxavir marboxil
- Xolair omalizumab
- Xpovio selinexor
- Xtandi enzalutamide
- Xyrem sodium oxybate
- Xywav calcium magnesium potassium sodium oxybates
- Yonsa abiraterone acetate
- Zokinvy lonafarnib
- Zorbtive somatropin
- Zyclara imiquimod
- Zytiga abiraterone acetate
Policy Alerts monitors Commercial and Medicare medical policies for changes. While medical Insurance carriers typically update medical policies annually, there are many reasons why they might review or update a policy. When reviews occur out of cycle they often go unnoticed. Policy Alerts keeps you updated when Payers make coverage changes to medical policies affecting your business.
Policy Alerts continuously monitors Commercial and Medicare Payer coverage information to keep you up-to-date on medical Insurance decisions in real-time. When changes occur, instant email alerts are delivered to your inbox. Clients have access to detailed coverage reports and medical policies through the interactive Policy Alerts Dashboard portal. Save time each month and keep focused on important Payer medical policy reviews and coverage decisions affecting your business!
Policy Alerts takes a client-focused hands-on approach and is constantly working to provide our customers with helpful insights and actionable analytics. We understand what our clients need and are dedicated to providing timely, accurate, and always up-to-date reports.
Health economic and reimbursement information provided by Policy Alerts is gathered from third-party sources and is subject to change without notice as a result of complex and frequently changing laws, regulations, rules and policies. All product and company names are trademarks™ or registered® trademarks of their respective holders. Use of them does not imply any affiliation with or endorsement by them. This information is presented for illustrative purposes only and does not constitute reimbursement or legal advice.
Related Posts
